Diversion Control Division, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

November

Final Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I (November 25, 2020)

Johnson Matthey Pharmaceutical Materials Inc. (November 23, 2020)

Lewis Leavitt III, M.D.; Decision and Order (November 19, 2020)

Suntree Pharmacy and Suntree Medical Equipment, LLC; Decision and Order (PDF) (November 19, 2020)

ECO Apothecary, LLC; Decision and Order (November 19, 2020)

Monica Ferguson, F.N.P., R.N.; Decision and Order (November 19, 2020)

Jeffrey M. Wolk, M.D.; Decision and Order (November 19, 2020)

Julie I. Dee, M.D.; Decision and Order (November 19, 2020)

Verne A. Schwager, M.D.; Decision and Order (November 19, 2020)

Jeanne E. Germeil, M.D. Decision and Order (PDF) (November 19, 2020)

Hil Rizvi, M.D.; Decision and Order (November 19, 2020)

Jonathan Rosenfield, M.D.; Decision and Order (November 19, 2020)

Navinta LLC (November 4, 2020)

Cerilliant Corporation (November 4, 2020)

Proposed Rule: Suspicious Orders of Controlled Substances (PDF) (November 2, 2020)

Interim Final Rule: Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment (PDF) (November 2, 2020)


October

Interim Final Rule: Placement of Oliceridine in Schedule II (October 30, 2020)

Final Rule: Implementation of the Combat Methamphetamine Epidemic Act of 2005; Retail Sales; Notice of Transfers Following Importation or Exportation (October 29, 2020)

Contract Pharmacal Corp. (October 28, 2020)

ARCOS Retail Drug Summary Report (Jan-Jun 2020)

API GLOBAL LLC (October 27, 2020)

Mylan Pharmaceuticals (October 27, 2020)

Mylan Technologies Inc. (October 23, 2020)

Final Rule: Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008; Correction (October 22, 2020)

Noramco Inc. (October 22, 2020)

Kinetochem LLC (October 22, 2020)

30-Day Notice: Drug Questionnaire (October 15, 2020)

Synthcon, LLC (October 14, 2020)

Euticals, Inc. (October 14, 2020)

Purisys, LLC (October 9, 2020)

Steven A. Holper, M.D.; Decision and Order (October 9, 2020)

Wayne Pharmacy; Decision and Order (October 8, 2020)

MMJ Biopharma Cultivation, Inc. (October 8, 2020)

Barbara D. Marino, M.D.; Decision and Order (October 7, 2020)

Jacqueline G. Curtis, M.D.; Decision and Order (October 7, 2020)

Stacey Lynne Schirmer, M.D.; Decision and Order (October 7, 2020)

Interim Final Rule: Placement of Remimazolam in Schedule IV (October 6, 2020)

Halo Pharmaceutical, Inc. (October 6, 2020)

S&B Pharma, LLC (October 6, 2020)

Eli Elsohly Laboratories (October 6, 2020)

Wildlife Laboratories, LLC (October 6, 2020)

Proposed Rule: Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017 (October 5, 2020)

Final Order: Placement of Crotonyl Fentanyl in Schedule I (October 2, 2020)


September

Final Rule: Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (September 30, 2020)

Proposed Rule: Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a DEA Registration (September 30, 2020)

Fisher Clinical Services, Inc. (September 24, 2020)

Caligor Coghlan Pharma Services (September 23, 2020)

Rhodes Technologies (September 18, 2020)

Cambrex High Point, Inc. (September 18, 2020)

Nalas Engineering Services, Inc. (September 18, 2020)

Bright Green Corporation (September 18, 2020)

Fisher Clinical Services, Inc. (September 18, 2020)

Organix Inc. (September 14, 2020)

Cambridge Isotype Lab (September 14, 2020)

Cerilliant Corporation (September 14, 2020)

Novitium Pharma LLC (September 14, 2020)

60-Day Notice: Drug Questionnaire (DEA-341) (September 9, 2020)

Nanosyn Inc. (September 9, 2020)

Cayman Chemical Company (September 8, 2020)

Cambridge Isotope Laboratories (September 8, 2020)

Aspen API, Inc. (September 8, 2020)

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 (September 1, 2020)

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021 (September 1, 2020)


August

Heavenly Care Pharmacy; Decision and Order (PDF) (August 28, 2020)

Proposed Rule: Placement of N-Ethylpentylone in Schedule I (August 27, 2020)

Temporary Rule: Extension of Temporary Placement of N-Ethylpentylone in Schedule I of the Controlled Substances Act (August 27, 2020)

Interim Final Rule: Implementation of the Agriculture Improvement Act of 2018 (August 21, 2020)

Final Rule: Placement of Cenobamate in Schedule V (August 20, 2020)

Temporary Order: Temporary Placement of Isotonitazene in Schedule I (August 20, 2020)

Morning Star Pharmacy & Medical Supply 1; Decision and Order (PDF) (August 19, 2020)

David Mwebe, M.D.; Decision and Order (August 19, 2020)

Cedarburg Pharmaceuticals (August 11, 2020)

Purisys, LLC (August 11, 2020)

National Center for Natural Products Research NIDA MPROJECT (August 11, 2020)

Mark D. Beale, M.D.; Decision and Order (August 11, 2020)

Cambrex High Point, Inc. (August 11, 2020)

Epic Pharma, LLC (August 11, 2020)

GE Healthcare (August 11, 2020)

Catalent CTS, LLC (August 11, 2020)

Tommy L. Louisville, M.D.; Decision and Order (August 10, 2020)

American Radiolabeled Chemicals, Inc (August 3, 2020)

Chattem Chemicals Inc (August 3, 2020)

Curium US LLC (August 3, 2020)


July

Proposed Rule: Reporting of Theft or Significant Loss of Controlled Substances (July 29, 2020)

Euticals Inc. (July 29, 2020)

Siegfried USA, LLC (July 29, 2020)

Salvatore Cavaliere, D.O.; Decision and Order (July 29, 2020)

Kaniz F. Khan-Jaffery, M.D.; Decision and Order (PDF) (July 29, 2020)

Hamada Makarita, D.D.S.; Denial of Application (July 29, 2020)

AMPAC Fine Chemicals Virginia, LLC (July 28, 2020)

Frederick M. Silvers, M.D.; Decision and Order (July 28, 2020)

Frank Joseph Stirlacci, M.D.; Decision and Order (July 27, 2020)

Final Rule: Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants (PDF) (July 24, 2020)

Ampac Fine Chemicals LLC (July 24, 2020)

Arizona Department of Corrections (July 24, 2020)

United States Pharmacopeial Convention (July 17, 2020)

Cambrex Charles City (July 17, 2020)

Proposed Rule: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I (July 13, 2020)

Extension of Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I of the Controlled Substances Act (July 13, 2020)

Purisys, LLC (July 9, 2020)

Usona Institute (July 8, 2020)

Galephar Pharmaceutical Research, Inc. (July 8, 2020)

Xcelience (July 8, 2020)

Lipomed (July 7, 2020)


June

Organic Standards Solutions International, LLC (June 22, 2020)

Proposed Rule: Temporary Placement of Isotonitazene in Schedule I (June 18, 2020)

Cambrex Charles City (June 17, 2020)

Woodfield Distribution, LLC (June 17, 2020)

Order with Opportunity for Comment: Exempt Anabolic Steroid Products (June 15, 2020)

VHG Labs DBA LGC Standards (June 15, 2020)

SpecGx LLC (Correction) (June 11, 2020)

Cardinal Health (June 11, 2020)

Honeoye Manufacturing (June 9, 2020)

Research Triangle Institute (June 9, 2020)

Final Rule: Listing of Ethylone in Schedule I of Controlled Substances (June 8, 2020)

Sigma Aldrich Research Biochemicals, Inc. (June 5, 2020)

Chemtos, LLC (June 5, 2020)

Nalas Engineering Services, Inc. (June 5, 2020)

Catalent Pharma Solutions, LLC (June 4, 2020)

Akorn, Inc. (June 4, 2020)

Bellwyck Clinical Services (June 4, 2020)

60-Day Notice: Application for Permit To Import Controlled Substances for Domestic and/or Scientific Purposes; DEA Form 357 (June 3, 2020)

60-Day Notice: Report of Loss or Disappearance of Listed Chemicals and Regulated Transactions in Tableting/Encapsulating Machines; DEA Forms 107, 452 (June 3, 2020)

60-Day Notice: Import/Export Declaration for List I and List II Chemicals; DEA Forms 486, 486A (June 3, 2020)

60-Day Notice: Application for Permit To Export Controlled Substances; Application for Permit To Export Controlled Substances for Subsequent Reexport; DEA Forms 161, 161R, 161R-EEA (June 3, 2020)

60-Day Notice: Controlled Substances Import/Export Declaration; DEA Form 236 (June 3, 2020)

Emergency Disaster Relief
Search for Year Round Pharmaceutical Disposal Locations.
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility